Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TIL
Strong SellSinkerInstil Bio, Inc. · Healthcare · United States · $51M · Avg Vol: $56K/d
9
StockRankGet insider-trade alerts
Q
27
V
36
M
20
P/E (TTM)
—
ROE
-25.3%
D/E
0.8x
Dividend %
—
COMPANY DESCRIPTION
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -34.40 | -24.00 | -11.39 | -10.70 | — | -4.40 |
| Shares | 6.5M | 6.5M | 6.5M | 6.8M | +4.3% | 6.8M |
| Debt | 79.9M | 86.1M | 86.9M | 85.2M | 2.2% | 87.4M |
| Equity | 363.6M | 225.8M | 169.4M | 113.9M | -32.1% | — |
| Op CF | -180.2M | -82.0M | -55.7M | -36.6M | — | -23.6M |
| Inv CF | 114.5M | 41.1M | 54.0M | 25.5M | — | — |
| Fin CF | 71.9M | 8.1M | 1.8M | 7.3M | — | — |
Loading 1Y...
PRICE (1Y)+3.1%
SMA 50SMA 200
Close
$7.36
RSI (14)
48.3
52W High
$26.48
From 52W High
0.3%
SCORE BREAKDOWN
Quality
27
ROIC
-33.4%22.5
ROE
-25.3%28.0
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-22.9%18.5
Piotroski
29.5
Int. Cover
-13.2x19.8
D/E Ratio
0.81x17.5
Current Ratio
21.67x96.5
Value
36
P/E (TTM)
—N/A
EV/EBITDA
-1.9x25.0
P/FCF
—N/A
P/B
0.5x97.6
P/S
—N/A
Div Yield
—N/A
Momentum
20
52W High %
28%6.6
RS 6M
-31%27.6
SMA 50/200
0.89x30.0
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
-233%2.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$51M
P/E (Forward)
-0.5x
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TIL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TIL | Instil Bio, Inc.(you) | $51M | 9 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%